All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

Clinical Value of Low Molecular Weight Heparin in Treatment of Pulmonary Heart Disease Complicated With Respiratory Failure

Author(s): M. FAN, XIANGXIANG YANG, T. DING, Y. CAO, Q. SI, JING BAI, Y. LIN AND X. ZHAO*
Department of Internal Medicine Cardiovascular, Pingliang People’s Hospital, Pingliang, Gansu744000, China; 1Department of Internal Medicine Cardiovascular, Affiliated Hospital of Gansu University of Traditional Chinese, No.1 Hezheng West Road, Chengguan District, Lanzhou, Gansu730020, China

Correspondence Address:
X. ZHAO, Department of Internal Medicine Cardiovascular, Affiliated Hospital of Gansu University of Traditional Chinese, No.1 Hezheng West Road, Chengguan District, Lanzhou, Gansu730020, China; E-mail: [email protected]


It is aimed to investigate the clinical value of low-molecular-weight heparin in treatment of pulmonary heart disease complicated with respiratory failure. Between January 2018 and April 2019, we included 120 pulmonary heart disease patients complicated with respiratory failure in this study and divided them into two groups using the double-blind, random method, i.e. the control group and the observation group, with 60 patients in each group. After admission, patients in two groups undertook the regular treatment, while those in the observation group additionally took low molecular weight heparin at 5000 U via subcutaneous injection, twice per d. Before and after treatment, arterial blood-gas indicators [partial pressure of carbon dioxide, partial pressure of oxygen and pH value] and the indicators of hemorheology (high blood viscosity, hematocrit and fibrinogen) and clinical efficacy were evaluated for patients in two groups. Prior to the treatment, comparison of the levels of partial pressure of carbon dioxide, partial pressure of oxygen, pH value, high blood viscosity, hematocrit and fibrinogen between two groups showed no significant differences, while after treatment, significant improvement was demonstrated in these indicators in the observation group as compared to those in the control group (p<0.05), but the difference in pH value showed no statistical significance (p>0.05). In the observation group, patients had an effectiveness rate of 88.33 % (53/60), significantly higher than 63.33 % (38/60) in the control group (p<0.05). Comparison of the time of oxygen uptake and incidence rate of complications showed no significant differences (p>0.05), while patients in the observation group had shorter hospitalization time [(14.7±0.4) d] than that [(16.9±0.3) d] in the control group (p<0.05). For pulmonary heart disease patients complicated with respiratory failure, medication of low-molecular-weight heparin gained promising efficacy, with significant improvement in the blood performance, ventilation, and heart and lung functions of patients, thereby increasing the survival rate and shortening the hospitalization time of patients. Thus, it is worthy of being promoted in clinical practice.

Full-Text | PDF